On October 27, 2025, the Clinical Research Center, Faculty of Medicine, Chulalongkorn University (Chula CRC) welcomed executives and specialists from the MSD Global Team (Merck Sharp & Dohme) for a site visit and strategic operational meeting.

A key agenda of the visit was to review the progress of the MK8527 (HIV PrEP) clinical trial and to reinforce the collaborative framework under the "MSD Clinical Research Development Program." This program represents a strategic partnership between MSD and the Faculty of Medicine, Chulalongkorn University.

The program is focused on new drug development, encompassing clinical trials from early phases through to Phase III and IV.

Chula CRC demonstrated its readiness and capabilities as a principal Clinical Trial Site, equipped to conduct complex studies adhering to international standards. The collaboration prioritizes several key therapeutic areas, including:

• HIV Disease

• Oncology Disease

• Pediatrics/Adolescent Therapeutic Disease

• Vaccine Trials

This visit from the MSD Global Team reflects a shared commitment to advancing medical innovation. Chula CRC is prepared to continue this partnership to achieve tangible outcomes and drive future public health advancements.